ASN: eGFR No Different With Sparsentan, Irbesartan in Focal Segmental Glomerulosclerosis
WEDNESDAY, Nov. 8, 2023 -- No significant differences are seen in the estimated glomerular filtration rate (eGFR) with sparsentan versus irbesartan among patients with focal segmental glomerulosclerosis (FSGS), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 8, 2023 Category: Pharmaceuticals Source Type: news
Sparsentan Bests Irbesartan for Preserving Kidney Function in IgA Nephropathy
(MedPage Today) -- PHILADELPHIA -- Sparsentan (Filspari) outperformed irbesartan in patients with IgA nephropathy over the 2-year phase III PROTECT trial.
Over a 110-week treatment period, those on sparsentan had an average 42.8% (95% CI -49... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 6, 2023 Category: Urology & Nephrology Source Type: news
Sparsentan Failed to Preserve Kidney Function Over Time in FSGS
(MedPage Today) -- PHILADELPHIA -- Treatment with sparsentan (Filspari) led to no significant differences in estimated glomerular filtration rate (eGFR) slope compared with irbesartan among patients with focal segmental glomerulosclerosis (FSGS... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 3, 2023 Category: Urology & Nephrology Source Type: news
UPDATED PRODUCT AND BATCH - Class 2 Medicines Recall various Marketing Authorisation Holders and parallel distributor companies, Irbesartan-containing products
There is one additional product and batch that has been added to this recall.
Further information on the affected batches and advice for healthcare professionals can be found on theMHRA website. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 1, 2021 Category: Drugs & Pharmacology Source Type: news
Health chiefs recall batches of blood pressure pills because they contain cancer-causing chemical
Blood pressure pill, irbesartan, taken by millions of Britons has been recalled after the UK's drug watchdog found unacceptable levels of a cancer causing chemical in nearly 45 batches. (Source: the Mail online | Health)
Source: the Mail online | Health - November 30, 2021 Category: Consumer Health News Source Type: news
Blood pressure pills recalled after chemical found with potential link to cancer
BATCHES of blood pressure drug irbesartan are being recalled, as a precaution, due to the presence of a chemical substance which has been linked to cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - November 30, 2021 Category: Consumer Health News Source Type: news
Class 2 Medicines Recall: Various Marketing Authorisation Holders and parallel distributor companies, Irbesartan-containing products
Specific batches of products are recalled by the Marketing Authorisation Holders and parallel distributor companies as a precautionary measure due to contamination with an impurity called 5-(4’- (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 30, 2021 Category: Drugs & Pharmacology Source Type: news
FDA: Yet Another Blood Pressure Medication Recall Due To Cancer Concerns
This time it ’s Lupin Pharmaceuticals Inc. recalling all batches of their irbesartan tablets as well as their irbesartan plus hydrochlorothiazide tablets. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 24, 2021 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news
Lupin Recalls Irbesartan & Hydrochlorothiazide/Irbesartan Tablets Lupin Recalls Irbesartan & Hydrochlorothiazide/Irbesartan Tablets
The voluntary nationwide recall was prompted by a possible impurity and affects all batches of the antihypertensive tablets.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 14, 2021 Category: Cancer & Oncology Tags: Cardiology News Alert Source Type: news
Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of All Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets Due to Potential Presence of N-nitrosoirbesartan Impurity
Baltimore, Maryland, October 14, 2021: Lupin Pharmaceuticals Inc. is voluntarily recalling the below-mentioned batches of Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets to the consumer level. As part of Lupin ’s ongoing assessment, analysis revealed that certain tested API batches (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 14, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Update on Class 2 Medicines Recall: Various Marketing Authorisation Holders and parallel distributor companies, Irbesartan-containing products
MHRA havemade an update to the Class 2 Medicines Recall: Various Marketing Authorisation Holders and parallel distributor companies, Irbesartan-containing products. The update is to an expiry date for (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - August 16, 2021 Category: Drugs & Pharmacology Source Type: news
